Andreas H. Wagner

Prof. Dr. Andreas H. Wagner

orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2017 in Biochemical Pharmacology
Verified
Journal Article
Closed access
MHMarkus Hecker
Markus Hecker
AWAndreas H. Wagner
Andreas H. Wagner

6 November 2017 in Journal of Inherited Metabolic Disease
Verified
Journal Article
Closed access
MHMarkus Hecker
Markus Hecker
AWAndreas H. Wagner
Andreas H. Wagner

12 April 2022 in Biochemical Pharmacology
Verified
Journal Article
Closed access
BMB. Morath
B. Morath
SSS. Sauer
S. Sauer
MZM. Zaradzki
M. Zaradzki
AWAndreas H. Wagner
Andreas H. Wagner

23 May 2018 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
MPMiruna A. Popa
Miruna A. Popa
STSibgha Tahir
Sibgha Tahir
JEJulia Elrod
Julia Elrod
SKSu Hwan Kim
Su Hwan Kim
FLFlorian Leuschner
Florian Leuschner
MHMarkus Hecker
Markus Hecker
Significance: In this study we have identified a mechanism that links pathophysiological ADAMTS13 deficiency to innate immunity and hemostasis by facilitating monocyte extravasation as a prerequisite for their subsequent on-site differentiation into proinflammatory macrophages under conditions of both physiological laminar flow and disturbed reduced flow, e.g., as occurs at atherosclerosis predilection sites. Our bioassay approach using patients’ plasma may become a useful diagnostic tool to assess ADAMTS13 activity ex vivo under conditions of near-physiological to atherosclerosis-prone arterial blood flow, which seems to be more relevant than the conventional static FRET-based assay method.

1 February 2005 in Arthritis Research & Therapy
Verified
Journal Article
Open access
MHMarion Hückel
Marion Hückel
USUta Schurigt
Uta Schurigt
AWAndreas H. Wagner
Andreas H. Wagner
RSRenate Stöckigt
Renate Stöckigt
PPPeter K Petrow
Peter K Petrow
RBRolf Bräuer
Rolf Bräuer
The transcription factor STAT-1 (signal transducer and activator of transcription-1) plays a pivotal role in the expression of inflammatory gene products involved in the pathogenesis of arthritis such as various cytokines and the CD40/CD40 ligand (CD40/CD40L) receptor-ligand dyad. The therapeutic efficacy of a synthetic decoy oligodeoxynucleotide (ODN) binding and neutralizing STAT-1 was tested in murine antigen-induced arthritis (AIA) as a model for human rheumatoid arthritis (RA). The STAT-1 decoy ODN was injected intra-articularly in methylated bovine serum albumin (mBSA)-immunized mice 4 h before arthritis induction. Arthritis was evaluated by joint swelling measurement and histological evaluation and compared to treatment with mutant control ODN. Serum levels of pro-inflammatory cytokines, mBSA-specific antibodies and auto-antibodies against matrix constituents were assessed by enzyme-linked immunosorbent assay (ELISA). The transcription factor neutralizing efficacy of the STAT-1 decoy ODN was verified in vitro in cultured synoviocytes and macrophages. Single administration of STAT-1 decoy ODN dose-dependently suppressed joint swelling and histological signs of acute and chronic arthritis. Delayed-type hypersensitivity (DTH) reaction, serum levels of interleukin-6 (IL-6) and anti-proteoglycan IgG titres were significantly reduced in STAT-1 decoy ODN-treated mice, whereas mBSA, collagen type I and type II specific immunoglobulins were not significantly affected. Intra-articular administration of an anti-CD40L (anti-CD154) antibody was similarly effective. Electrophoretic mobility shift analysis (EMSA) of nuclear extracts from synoviocytes incubated with the STAT-1 decoy ODN in vitro revealed an inhibitory effect on STAT-1. Furthermore, the STAT-1 decoy ODN inhibited the expression of CD40 mRNA in stimulated macrophages. The beneficial effects of the STAT-1 decoy ODN in experimental arthritis presumably mediated in part by affecting CD40 signalling in macrophages may provide the basis for a novel treatment of human RA.

1 June 2018 in Redox Biology
Verified
Journal Article
Open access
CSCheryl S. Sultan
Cheryl S. Sultan
ASAndrea Saackel
Andrea Saackel
ASAntonia Stank
Antonia Stank
TFThomas Fleming
Thomas Fleming
MFMaria Fedorova
Maria Fedorova
AWAndreas H. Wagner
Andreas H. Wagner
High levels of glucose and reactive carbonyl intermediates of its degradation pathway such as methylglyoxal (MG) may contribute to diabetic complications partly via increased generation of reactive oxygen species (ROS). This study focused on glutathione peroxidase-1 (GPx1) expression and the impact of carbonylation as an oxidative protein modification on GPx1 abundance and activity in human umbilical vein endothelial cells (HUVEC) under conditions of mild to moderate oxidative stress. High extracellular glucose and MG enhanced intracellular ROS formation in HUVECs. Protein carbonylation was only transiently augmented pointing to an effective antioxidant defense in these cells. Nitric oxide synthase expression was decreased under hyperglycemic conditions but increased upon exposure to MG, whereas superoxide dismutase expression was not significantly affected. Increased glutathione peroxidase (GPx) activity seemed to compensate for a decrease in GPx1 protein due to enhanced degradation via the proteasome. Mass spectrometry analysis identified Lys-114 as a possible carbonylation target which provides a vestibule for the substrate H2O2 and thus enhances the enzymatic reaction. Oxidative protein carbonylation has so far been associated with functional inactivation of modified target proteins mainly contributing to aging and age-related diseases. Here, we demonstrate that mild oxidative stress and subsequent carbonylation seem to activate protective cellular redox signaling pathways whereas severe oxidative stress overwhelms the cellular antioxidant defense leading to cell damage. This study may contribute to a better understanding of redox homeostasis and its role in the development of diabetes and related vascular complications.